Malignant Hyperthermia-Like Reaction in Pets: Dantrolene Treatment and Triggers

Last updated: May 16, 2026

What Malignant Hyperthermia Is and Why It Matters

Malignant hyperthermia is a rare but life-threatening syndrome where exposure to certain anesthetic drugs triggers uncontrolled muscle calcium release, runaway metabolism, severe hyperthermia, and progressive systemic deterioration. In humans and pigs the syndrome is well-characterized and tied to specific genetic mutations in the ryanodine receptor RYR1. In dogs and cats, true malignant hyperthermia is rare compared to humans and pigs, but malignant hyperthermia-like reactions do occur and require the same emergency response.

The condition is unpredictable. A patient may have had previous uneventful anesthetic events and then react during a subsequent procedure. The trigger may be a single inhalant exposure or the combination of an inhalant and other agents. Because the event is rare and unpredictable, the foundation of safety is recognition — knowing the signs early, having the antidote available, and treating aggressively before the syndrome cascades into multi-organ failure.

The Triggers

The classic triggers are volatile inhalant anesthetics — halothane historically being the strongest trigger, with isoflurane, sevoflurane, and desflurane retaining some triggering potential. Halothane is no longer used in U.S. veterinary practice; modern isoflurane vs sevoflurane protocols carry less risk than halothane did but are not entirely risk-free.

The depolarizing neuromuscular blocker succinylcholine is also a documented trigger. Succinylcholine is rarely used in modern small-animal veterinary anesthesia, in part because of MH risk and in part because non-depolarizing alternatives are widely available. Stress and hyperthermia from environmental causes can theoretically contribute in susceptible patients.

Non-triggering anesthetic agents are propofol, alfaxalone, ketamine, etomidate, opioids, benzodiazepines, alpha-2 agonists, and acepromazine. For a patient with documented or suspected MH risk, the anesthetic plan substitutes total intravenous anesthesia using non-triggering injectable agents in place of inhalant gas. See propofol vs alfaxalone induction for the injectable options.

Which Patients Are at Risk

In dogs, MH-like reactions have been reported in Greyhounds and other sighthounds, German Shepherds, Border Collies, English Springer Spaniels, Pointers, Labrador Retrievers, and other breeds. No single breed has been confirmed to carry the human-style RYR1 mutation reliably, but susceptibility appears to vary across breeds and individuals. In pigs, specific RYR1 mutations in some commercial breeds are well-documented and cause clinically significant MH. In cats, MH-like reactions have been reported but are even rarer.

A family history of an anesthetic event with unexplained hyperthermia in a related dog or cat is the most actionable warning sign. If your pet had a previous procedure complicated by intra-operative hyperthermia and muscle rigidity, the patient is treated as MH-susceptible for future procedures regardless of confirmatory testing.

Recognizing the Signs During Anesthesia

The earliest sign is usually a rapid, unexplained rise in end-tidal CO2 (ETCO2) on the capnograph that does not respond to increasing ventilation. Capnography is therefore the single most important monitor for catching MH early — see anesthetic monitoring essentials. Heart rate climbs, blood pressure may be variable but often elevated initially, and skeletal muscle rigidity develops — particularly the jaw and the limbs.

Core body temperature climbs rapidly — often 1 to 2 degrees Celsius per fifteen to thirty minutes — and continues climbing despite cessation of warming and active cooling. Blood gas analysis (where available) shows severe metabolic acidosis and respiratory acidosis. Hyperkalemia develops as damaged muscle cells release potassium. Urine becomes dark (cola-colored) as rhabdomyolysis releases myoglobin into circulation.

Late signs are cardiovascular collapse, ventricular arrhythmias, disseminated intravascular coagulation, and acute kidney injury from myoglobinuric pigment nephropathy. Without rapid intervention the syndrome is fatal.

Emergency Treatment

The single most important action is to discontinue the triggering agent immediately. The vaporizer is turned off, the anesthetic circuit is purged with one hundred percent oxygen at high flow, and if possible the breathing circuit is switched to a fresh non-contaminated machine. The patient is hyperventilated with one hundred percent oxygen to address acidosis.

Dantrolene is the specific antidote. It works by inhibiting calcium release from the sarcoplasmic reticulum in skeletal muscle, breaking the metabolic cascade. Supply of dantrolene in veterinary practice is limited — it is expensive, has a short shelf life after reconstitution, and is stocked routinely only in specialty hospitals. Some referral centers maintain a dantrolene supply specifically for MH emergencies; many general practices do not.

Supportive treatment runs in parallel. Active cooling — cool IV fluids, room-temperature water on the body (not ice water, which causes vasoconstriction), fans, cool body-cavity irrigation if open — addresses the temperature. IV fluids support blood pressure and protect kidneys from myoglobin damage; the principles match crystalloid vs colloid fluid therapy. Bicarbonate corrects acidosis. Insulin and dextrose treat hyperkalemia. Calcium gluconate stabilizes cardiac membranes against hyperkalemic arrhythmias.

Distinguishing MH From Other Causes of Hyperthermia

Not every intra-operative temperature rise is MH. Heatstroke from environmental heating with the warming blanket, excessive heat from the surgical lights, or thick coats with full body warmer coverage can produce hyperthermia in anesthetized patients. The distinguishing features of MH are the speed of temperature rise, the failure to respond to removing heat sources, the muscle rigidity, the rapid ETCO2 climb, and the severe metabolic acidosis.

Other causes of intra-operative temperature elevation are infectious (sepsis emerging during surgery), endocrine (rare thyroid storm in hyperthyroid cats under stress), and medication reactions. The differential is part of the emergency thought process, but treatment for MH should begin immediately when MH is suspected — waiting for confirmation costs lives.

Prevention in Susceptible Patients

For pets with a documented prior MH-like reaction or a strong family history, the anesthetic plan replaces inhalant gas with a total intravenous anesthesia (TIVA) protocol. Propofol or alfaxalone infusion provides maintenance anesthesia without the inhalant trigger. Opioids, benzodiazepines, and ketamine combinations are options for premedication and analgesia. The team prepares dantrolene before the procedure and has cooling equipment immediately available.

Referral to an ACVAA-diplomate specialty hospital is strongly considered for MH-susceptible patients undergoing any non-emergency procedure. The specialist team has experience, equipment, and antidote on hand. For emergency procedures in suspected MH-susceptible patients, the closest equipped emergency hospital is appropriate.

After an MH-Like Event

Patients who survive an MH-like event are typically hospitalized for several days. Acute kidney injury from myoglobinuric pigment nephropathy is the most common surviving complication and is managed with continued fluid therapy, monitoring of renal values, and supportive care — see acute kidney injury in dogs. Coagulopathy may persist for days and requires monitoring; for severe DIC, see disseminated intravascular coagulation.

The patient is considered MH-susceptible for life. Future anesthetic events must use TIVA protocols and be planned with the team that managed the original event or another anesthesia specialist. The owner should keep a written record of the event — drugs given, signs noted, treatment response — and bring this to every future veterinary visit.

Genetic Testing and Family History

Genetic testing for canine MH susceptibility exists for some breeds and specific RYR1 variants but is not universally available or routinely recommended. The test result is informative but not definitive; a negative test does not guarantee safety, and a positive test does not always predict a clinical event. For most pet owners without a family history of MH, routine genetic testing is not part of pre-anesthetic workup.

If a dog from a recognized breeding program has an MH event, breeders are typically informed so they can avoid breeding affected lines. This is part of responsible breeding practice in breeds with documented susceptibility.

The Emotional Aftermath

An MH-like reaction is one of the most traumatic events possible for an owner. The procedure was supposed to be routine — a dental cleaning, a spay, an elective surgery — and the pet did not recover or barely survived. The unexpected nature of the event, the inability to have predicted it, and the speed of the deterioration all complicate the grief and processing.

For owners who have lost a pet to an MH-like reaction or to anesthetic complications more broadly, the ASPCA Pet Loss Hotline (877-474-3310) offers confidential, free support. Pet loss resources are also available at pet loss support resources. The reaction is not the owner’s fault, and it is rarely the team’s fault — these are unpredictable events even with excellent planning.

What Owners Can Do

If your pet has had a previous anesthetic event with unexplained hyperthermia, muscle rigidity, or unexpectedly severe recovery, bring those records to every future procedure. Discuss whether your pet should be treated as MH-susceptible for future anesthesia. Ask the team about TIVA capability and dantrolene availability. For non-emergency procedures, consider whether a referral hospital is the safer venue.

For routine procedures in pets without a history, the basic pre-anesthetic workup and a competent monitoring setup are the standard of care. MH is rare enough that universal precautions for it are not needed, but the team should have a plan if it occurs.

When to Consult an ACVAA Specialist

ACVAA-diplomate consultation is appropriate for pets with documented MH history, strong family history, or breeds with reported susceptibility undergoing major surgery. The specialist may continue care at the referral hospital or consult on a TIVA protocol that proceeds at the primary clinic with appropriate preparation. Your primary veterinarian is the coordinator and can initiate referral when warranted.

For pets who have had multiple anesthetic events without problems, the risk of a future MH-like event remains low and routine planning is appropriate. The team should still have a general plan for intra-operative hyperthermia — see anesthetic monitoring essentials for the standard monitoring that catches it early.

Frequently Asked Questions

Could my pet have MH and we just do not know it?

True MH is rare in dogs and cats, so the statistical answer is no — most pets without a history of an MH-like event will never have one. The clinical answer is that the syndrome is unpredictable; even with no history, an MH-like reaction can occur. This is exactly why intra-operative monitoring, particularly capnography, is so important.

Is dantrolene always available if my pet has a reaction?

No — dantrolene is expensive and has a limited shelf life, so many general practices do not stock it routinely. Specialty hospitals and emergency centers are more likely to have it. If your pet has a documented MH history, ask in advance whether dantrolene is available at the clinic where the procedure will happen.

Should I avoid anesthesia for my pet because of MH risk?

Not unless there is a specific history that suggests susceptibility. For most pets, the risk of MH is low and the benefit of necessary procedures (dental care, spay/neuter, mass removal, dental extractions) clearly outweighs it. For pets with documented risk, anesthesia is still possible — it is the protocol that changes, not the decision.

What signs should I report to the vet about previous anesthesia?

Anything unexpected — prolonged recovery, vomiting that worried the team, intra-operative hyperthermia, muscle rigidity, dark urine after surgery, any event that prompted treatment beyond routine recovery. The vet can decide whether the event is consistent with MH-like reaction or with another cause.

Is there a way to test my pet for MH susceptibility?

Genetic testing exists for some breeds and RYR1 variants but is not routinely available or definitive. For most pet owners, the practical screening is family history and previous anesthetic events. If your pet’s breeder or breed-specific community has identified MH events, that information is worth sharing with your vet.